spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

SCORR Marketing and Applied Clinical Trials Release Report on Collaborative R&D in the Drug Development Industry

Applied Clinical Trials

Study on collaboration in the life sciences industry

Industry Kearney, Neb., Oct. 18, 2017

SCORR Marketing, a global health science marketing and communications firm, and Applied Clinical Trials have released a new study, Collaborative R&D Survey Report. The report details the extent to which collaboration in the life sciences industry occurs and provides insight into the factors that influence this collaboration.

“To fight the growing complexity and costs of drug development, drug sponsors are turning to a variety of strategies, one of which is collaborating on research and development (R&D),” said Anne-Marie Hess, senior strategic advisor at SCORR. “To help the industry better understand this strategy, we gathered information about attitudes toward collaborative R&D, its benefits and risks, which groups participate in such collaborations and why some partnerships are more productive than others.”

In addition, this report has information on why those in the industry think these arrangements are increasing, which stakeholders are more receptive to R&D partnerships and what types of medicines, therapeutic areas and medical devices will see more research and development through collaboration in the years ahead.

“Shared expertise and more efficient resource allocation were the two greatest perceived benefits of collaborative R&D,” said Lisa Henderson, group content director, Applied Clinical Trials, and Pharmaceutical Executive at UBM Americas. “What surprised us throughout the survey was the large discrepancy we found in some areas based on the respondents’ demographics — where their company was headquartered, the size of their company and their particular field.”

About SCORR Marketing
SCORR Marketing is the leading marketing and communications firm in the health sciences industry. We partner with organizations involved in global research, development and commercialization of biopharmaceutical and device products and the delivery of health care products and services. At SCORR, we achieve results for our clients by applying our proven, disciplined approach to synthesize market intelligence, strategy and creativity. We have locations across North America and Europe. For more information, visit www.scorrmarketing.com.
email lisa.henderson@ubm.com
email 485 Route 1 South Building F, Suite 210 Iselin, NJ 08830
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Huge boom in Korean Pharma reported at CPhI Korea

Amsterdam, 19th September 2019: The recently-closed CPhI Korea – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – has seen a surge in growth across domestic and international pharma companies, as well as a sizable rise in overall attendees. As reported earlier this year in the provisional findings of the CPhI Pharma Index[1], Korea has seen a rapid growth in its international reputation (seeing its ‘overall competitiveness’ rise 14% in the last two years), which is now translating into a sizable growth in the market and at the event.
More info >>


White Papers

Soothing the Logistical Headache of Clinical Trials

Equilibrium Travel Management

As many as 30 per cent of subjects on phase three clinical studies drop out.  Gruelling schedules, high travel costs and time waiting for expense reimbursement can all be factors in these fall rates, and this can be very problematic, delaying or even leading to the cancellation of the trial.  It is crucial to keep subjects motivated, and through efficient travel and expense management, this can be achieved.
More info >>

Industry Events

BioTrinity 2020

28-29 April 2020, Etc Venues, London

BioTrinity is a long-running and highly regarded two day life sciences conference that takes place in Central London from 28-29 April. BioTrinity focuses on partnering, investment and collaboration and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement